

Notice of Allowability

Application No.

09/884,196

Examiner

F. Pierre VanderVegt

Applicant(s)

BLUMBERG, RICHARD S.

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to paper filed June 21, 2004.
2. ☒ The allowed claim(s) is/are 11,12,15,41,42,45 and 57-64.
3. ☒ The drawings filed on 19 June 2001 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 - * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413),
Paper No./Mail Date 09162004.
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with John Van Amsterdam on September 16, 2004.

The application has been amended as follows:

IN THE CLAIMS:

In claim 11, line 4 of the claim, the phrase --, CD66a, on a killer T cell-- has been inserted after the recitation of "polypeptides".

In claim 11, line 5 of the claim, the recitation of "or a" has been replaced by --specific for said biliary glycoprotein or an antigen-binding--.

In claim 11, line 6 of the claim, the phrase --on the killer T cell-- has been inserted after the recitation of "glycoprotein".

In claim 15, line 4 of the claim, the phrase --, CD66a, on a killer T cell-- has been inserted after the recitation of "polypeptides".

In claim 15, line 5 of the claim, the recitation of "a" has been replaced by --an isolated--.

In claim 15, line 6 of the claim, the term --isolated-- has been inserted before "ligand".

In claim 15, line 6 of the claim, the phrase --on the killer T cell-- has been inserted after the recitation of "polypeptides".

In claim 15, line 7 of the claim, the term --isolated-- has been inserted before "ligand".

In claim 41, line 4 of the claim, the phrase --, CD66a, on a killer T cell-- has been inserted after the recitation of "polypeptides".

In claim 41, line 6 of the claim, the recitation of "or a" has been replaced by --specific for said biliary glycoprotein or an antigen-binding--.

In claim 41, line 6 of the claim, the phrase --on the killer T cell-- has been inserted after the recitation of "glycoprotein" at the end of the claim.

In claim 45, line 4 of the claim, the phrase --, CD66a, on a killer T cell-- has been inserted after the recitation of "polypeptides".

In claim 45, line 5 of the claim, the recitation of "a" has been replaced by --an isolated--.

In claim 45, line 6 of the claim, the term --isolated-- has been inserted before "ligand".

In claim 45, line 7 of the claim, the phrase --on the killer T cell-- has been inserted after the recitation of "polypeptides".

In claim 45, line 7 of the claim, the term --isolated-- has been inserted before "ligand".

In claim 58, the term --specific-- has been inserted after "CD66a".

In claim 59, line 2 of the claim, the recitation of "N-domain" has been replaced by the term --N-terminal domain--.

In claim 59, both recitations of "domains" have been replaced by --domain--.

In claim 61, the term --specific-- has been inserted after "CD66a".

In claim 62, line 2 of the claim, the recitation of "N-domain" has been replaced by the term --N-terminal domain--.

In claim 62, both recitations of "domains" have been replaced by --domain--.

In claim 63, line 1 of the claim, the term "molecule" has been replaced by --polypeptide--.

In claim 64, line 1 of the claim, the term "molecule" has been replaced by --polypeptide--.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00; Alternate Fridays 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

F. Pierre VanderVegt, Ph.D. *PV*
Patent Examiner
September 16, 2004

Christina Chan
CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600